#Cell Culture Media Market

[mitalipingale]

The Cell Culture Media Market in 2023 is US$ 4.58 billion, and is expected to reach US$ 11.7 billion by 2031 at a CAGR of 12.50%.

[neha24blog]

Cell Culture Media Market Focusing On The Basis Of Product, Application, Region And Forecast 2030: Grand View Research Inc.

Cell Culture Media Market Focusing On The Basis Of Product, Application, Region And Forecast 2030: Grand View Research Inc.

San Francisco, 5 Nov 2022: The Report Cell Culture Media Market Size, Share & Trends Analysis Report By Product (Serum-free Media, Classical Media), By Type (Liquid Media, Semi-solid And Solid Media), By Application, By End-user, By Region, And Segment Forecasts, 2022 – 2030 The global cell culture media market size is expected to reach USD 10.2 billion by 2030, according to a new report by…

[rootsanalysis-blog]

VIRAL VACCINE CELL CULTURE MEDIA: OVERALL MARKET LANDSCAPE

Innovation is considered to be one of the key drivers of the pharmaceutical industry. Over the past few decades, various technological advances and a few fortuitous discoveries have significantly changed the practice of medicine. One such advancement that came into light was the development of vaccines, which have demonstrated significant therapeutic potential.

  Over time, vaccine research has evolved significantly, which is now being driven by several innovative technologies, including those involving the use of recombinant deoxyribonucleic acid (DNA) and nucleic acids. Further, with the discovery of more disease targets, players engaged in vaccine development have shifted their focus towards the development of vaccines that target a myriad of disease indications other than infectious diseases. In order to mitigate the aforementioned challenges, pharma and biotech companies are gradually adopting viral vaccine cell culture media for vaccines manufacturing. 

 A vaccine is a biological substance that is used to stimulate the host’s immune system against a specific disease. It is worth highlighting those vaccines are also referred to as immunizers, due to their ability to take advantage of the host’s natural immune system to prevent illnesses. Generally, the vaccines contain a weakened or an inactivated (killed) form of a virus / a small (in virulent) part of the virus, which is called the antigen. Vaccines help the immune system recognize the antigen as a foreign entity or invading germ, thereby, resulting in the production of antibodies. This process aids the immune system in generating a memory against the specific pathogen so that if the host is attacked by the same pathogen in the future, the body can generate an illicit response.

 To request a sample copy / brochure of this report, please visit link

https://www.rootsanalysis.com/reports/viral-vaccine-cell-culture-media-market/request-sample.html

 Viral vaccines were first produced in the early 1940s, using embryonated chicken eggs to replicate a broad variety of viruses. Over 30 human vaccines, manufactured using this technique, have been licensed; however, the production capacity associated with this method was limited due to the unavailability of fertilized eggs. Further, in 1950s, an alternative technology based on animal cell culture, which used primary cells as substrate, was developed. Then, in the late 1960s, continuous cell lines were recognized as suitable hosts for human vaccine production, however, the first production process using this technique was established in 1977. One of the key objectives of this report was to evaluate the current opportunity and the future potential associated with the viral vaccine cell culture media market, over the coming decade. We have developed an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. 

  Cell cultures can be broadly classified into two categories, namely adherent and suspension cell cultures.

§  Adherent Cell Culture: As the name suggests, these cells must be attached to a surface to grow. These cells can be cultured in flasks, roller bottles and other cell culture vessels capable of handling anchorage-dependent cell types. As most of the tissue-derived cells in the body require an extracellular matrix for growth and proliferation, this method provides scalable options, such as mimicking a microenvironment. In addition, some adherent platforms provide the benefit of visualization through a microscope.

§  Suspension Cell Culture: In this process, cells or cluster of cells are allowed to function and multiply in an agitated growth medium. Suspension cells can be cultured in small-scale vessels, such as spinner flasks or large-scale vessels (single-use bioreactors). These cells offer a vast range of scalability, thereby, making it a preferred option for manufacturers in order to increase their operational efficacy. In fact, the nutrients can be continually adjusted in these cell cultures, depending on their usage and need of the cells. However, suspension cell culture lacks the benefit of direct visualization. In addition, the shear force and stress exerted due to the continuous agitation of the media in suspension culture are detrimental to many cell types, especially anchorage-dependent primary and stem cells.

 For additional details, please visit link https://www.rootsanalysis.com/reports/viral-vaccine-cell-culture-media-market.html or email sales@rootsanalysis.com

 You may also be interested in the following titles:

1.       Targeted protein degradation market, 2022-2035

2.       Cell Therapy Manufacturing Market, 2021-2030

3.       Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 Contact:

Ben Johnson

+1 (415) 800 3415

+44 (122) 391 1091

Ben.johnson@rootsanalysis.com

[colinwilson11]

Viral Vaccine Cell Culture Media Market Will Grow At Highest Pace Owing To Rising Prevalence Of Viral Infections

Viral vaccine cell culture media are essential growth mediums required for the propagation of viruses, used in the manufacturing of viral vaccines. It provides necessary nutrients to sustaining and propagation of cells outside of living organism. The composition of viral vaccine cell culture media varies depending on specific requirements and types of viruses being cultivated. It contains necessary salts, amino acids, proteins, vitamins and other organic compounds essential for growth of cells. The advantages associated with viral vaccine cell culture media include standardized and defined composition, ease of scale-up for large-scale manufacturing, and supporting growth of anchorage-dependent and suspension-adapted cells. The need for viral vaccine cell culture media is growing owing to rising incidences of viral infections and technological advancements in vaccine development.

The Viral Vaccine Cell Culture Media Market is estimated to be valued at US$ 1.8 Bn in 2024 and is expected to exhibit a CAGR of 5.8 % over the forecast period 2024-2031.

Key Takeaways

Key players operating in the viral vaccine cell culture media are Thermo Fisher Scientific, Merck, Sartorius,Creative Biolabs, Xell. Thermo Fisher Scientific dominates the market with wide range of viral vaccine cell culture media products.

Rising prevalence of viral infections such as influenza, COVID-19, hepatitis, and others is driving the demand for viral vaccines exponentially. As viral vaccines are manufactured using cell culture technologies, their growing demand is directly fueling the viral vaccine cell culture media market.

Advancements in cell culture technologies, serum-free and chemically defined media are helping overcome issues related to undefined compositions and lot-to-lot inconsistencies. These technologies are supporting more reproducible and scalable manufacturing of viral vaccines.

Market Trends

Serum-free and chemically defined media - These media eliminates risks of contamination from animal-derived components and assists consistent performance during vaccine production. Major players are focusing on development of serum-free formulations.

Single-use bioreactors and technologies - Single-use technologies are helping achieve flexible, consistent and scalable production compared to conventional stainless-steel bioreactors. This trend is positively impacting the viral vaccine cell culture media market.

Market Opportunities

Rising viral vaccine production in developing economies due to increasing disease burden is creating opportunities for viral vaccine cell culture media manufacturers to expand in emerging markets. Adoption of continuous manufacturing technologies using perfusion platforms can further improve productivity and efficiency of viral vaccine production. This presents lucrative opportunities for media manufacturers.

Impact Of COVID-19 On Viral Vaccine Cell Culture Media Market Growth

The outbreak of COVID-19 pandemic has severely impacted the growth of viral vaccine cell culture media market globally. The increased demand for vaccine development caused disturbance in the supply chain and manufacturing process of cell culture media. The lockdowns imposed by governments across various countries led to temporary closure of production facilities and disrupted import-export activities. This affected the availability of raw materials and components required for manufacturing cell culture media. Furthermore, restrictions on travel and transportation made it difficult for companies to conduct clinical trials and testing of vaccines under development.

However, with gradual lifting of lockdowns and resumption of business operations, the market is expected to regain lost momentum in post-COVID times. There is surge in R&D funding from governments and private organizations towards development of vaccines against coronavirus. This has boosted the demand for cell culture media from biopharmaceutical companies. Various start-ups and established players have entered into strategic collaborations with research institutes working on COVID-19 vaccines. They are focusing on expanding their production capacities to meet the growing requirements. Moreover, shift towards single-use technologies and automated solutions is expected to enhance production efficiency. Advancements in cell culture protocols will further drive the market growth in coming years.

Geographically, North America holds the major share of viral vaccine cell culture media market in terms of value, led by substantial research funding and presence of leading biopharma companies. Asia Pacific is emerging as the fastest growing regional market, supported by increasing government initiatives, improving healthcare infrastructure and growth of biosimilars industry in China and India. Recently, several Chinese manufacturers have started offering antibody and cell-based therapeutics against coronavirus. This is likely to boost the uptake of viral cell culture media in Asia Pacific post pandemic.

Impact Of COVID-19 On Viral Vaccine Cell Culture Media Market Growth In India

The COVID-19 outbreak hit India during the initial months of 2020. The country went into a nationwide lockdown enforcing travel restrictions and closure of non-essential services. This impacted the biopharmaceutical industry and temporarily disrupted the supply of cell culture media. Local production was halted as workforce mobility was constrained. Import of critical raw materials from other countries also reduced due to global supply chain disarray.

As a result, several vaccine developers faced challenges in terms of insufficient stock of cell culture media for ongoing R&D activities. Their pre-clinical research and clinical trials got delayed. However, as the lockdown rules were relaxed phase-wise, the Indian government initiated measures to resume operations following strict safety norms. It provided regulatory clearances and financial incentives for ramping up indigenous manufacturing of vaccine components including cell culture media.

India currently holds around 8-10% share of global biologics production. Post pandemic, efforts are being directed towards building self-reliance in vaccine manufacturing. Local players are augmenting their production capacities of viral cell culture media in collaboration with research institutes. Additionally, foreign companies are also evaluating India as an alternative manufacturing hub due to lower costs and large talent pool availability. Thus, India is anticipated to be one of the fastest growing regional markets for viral vaccine cell culture media in coming years.

Get more insights on this topic:  https://www.trendingwebwire.com/viral-vaccine-cell-culture-media-market-set-to-grow-due-to-advancements-in-cell-culture-techniques/

Author Bio

Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups. (LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)

What Are The Key Data Covered In This Viral Vaccine Cell Culture Media Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Viral Vaccine Cell Culture Media Market's growth between 2024 and 2031.

:- Accurate calculation of the size of the Viral Vaccine Cell Culture Media Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Viral Vaccine Cell Culture Media Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Viral Vaccine Cell Culture Media Market vendors

FAQ’s

Q.1 What are the main factors influencing the Viral Vaccine Cell Culture Media Market?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top Viral Vaccine Cell Culture Media Market companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the Viral Vaccine Cell Culture Media Market’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it

[marketinsightsbusiness]

Gene Therapy Cell Culture Media: The Backbone of Advanced Medicine

Gene therapy cell culture media are essential for the success of gene therapies, providing the critical environment needed for cell growth and maintenance. As gene therapy continues to advance, the demand for high-quality cell culture media is on the rise. Stay informed about the latest trends and developments in this rapidly growing market.

For More Details Click Here

[bhushans]

Bridging the Gap: How the Global Cell Culture Media Market is Expanding Access to Care

The global cell culture media market is expected to have steady growth and, by 2034, be valued at an estimated US$6,699.93 million. From a market value of US$3,513.8 million in 2024, this amounts to a Compound Annual Growth Rate (CAGR) of 6.66% during the forecast period.

In the life sciences sector, the cell culture market is expanding quickly and is essential to many types of research, medication development, and biotechnology applications. The practice of cultivating and preserving cells outside of their natural habitat in a controlled environment is known as cell culture. These cultured cells are an invaluable resource for scientists and researchers because they offer important insights into disease causes, cell behavior, and treatment responses.

Preview Next-Level Insights Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-14366

The desire for personalized medication and the rising demand for biopharmaceutical goods are the main factors driving the growth of the cell culture industry. Pharmaceutical companies are extensively investing in cell culture technology to create new medications and enhance existing ones, as the prevalence of chronic diseases rises. The need for sophisticated cell culture methods has also increased as a result of the growth of tissue engineering and regenerative medicine.

The market is also expanding because to creative solutions and technological breakthroughs. To better replicate in vivo settings, scientists are always creating better culture medium, bioreactors, and 3D cell culture systems. These developments enhance cell viability, productivity, and overall efficiency, meeting the growing requirements of the biotechnology and pharmaceutical sectors.

Competitive Landscape:

Important companies like Avantor, Inc., Thermo Fisher Scientific, Inc., Caisson Laboratories Inc., Becton Dickinson and Company, Lonza Group AG, Bio-Rad Laboratories, Inc., General Electric Company, etc. are present in the worldwide cell culture media market.

Many businesses are making significant investments in R&D to develop novel and specialized formulations of cell culture medium. The aforementioned tasks involve creating specified and serum-free media, refining current formulations, and integrating cutting-edge technology to fulfill the dynamic requirements of biopharmaceutical and life sciences research.

Recent Developments

On July 12, 2023, Merck announced the expansion of its Lenexa, Kansas facility, making it the company’s largest dry powder cell culture media facility and Center of Excellence in North America.

In October 2023, London-based startup Multus Biotechnology focused on cutting the cost of cell culture media for cultivated meat by leveraging AI to optimize formulation efficiency. The startup addresses challenges in ingredient quality, scalability, and bioprocess productivity, aiming to enhance the sustainability and cost-effectiveness of cell culture media.

On July 27, 2023, MilliporeSigma invested $25 million to expand its cell culture media production facility in Lenexa, Kansas. The expansion included 98,000 ft2 of lab space, reinforcing the company’s commitment to meeting the increasing demand for cell culture media. Lenexa now serves as one of the three global centers of excellence for dry powder cell culture media manufacturing.

Key Companies in the Market:

Avantor, Inc.

Thermo Fisher Scientific, Inc.

Caisson Laboratories Inc.

Becton Dickinson and Company

Lonza Group AG

Bio-Rad Laboratories, Inc.

General Electric Company

Cell Culture Technologies LLC

Corning Incorporated

Fujifilm Holdings Corporation

Hi Media Laboratories Pvt. Ltd.

Merck & Co., Inc.

Market Segmentation:

By Type:

Serum-free Media

CHO Media

HEK 293 Media

BHK Media

VERO Cell Media

Insect Cell Media

Serum-free Stem Cell Media

CAR T-cell Media

Other Serum-free Media

Classical Media & Salts

Stem Cell Culture Media

Specialty Media

Chemically defined Media

Other Cell Culture Media

By Application:

Biopharmaceutical Production

Monoclonal antibodies

Cancer Research

Vaccines production

Other therapeutic proteins

Diagnostics

Drug Screening & Development

Tissue Engineering & Regenerative Medicine

Cell and gene therapy

Other tissue engineering & regenerative medicine applications

Other Application

By End User:

Pharmaceutical & Biotechnology Companies

Hospitals & Diagnostic Laboratories

Research & Academic Institutes

Others

By Region:

North America

Latin America

Europe

Asia Pacific

Middle East and Africa

[karanresearchlayer]

CHO Cell Culture Media Market 2030 Has Huge Growth In Industry

CHO (Chinese Hamster Ovary) cell culture media are specifically formulated nutrient solutions used to support the growth, maintenance, and production of CHO cells in laboratory and industrial settings. CHO cells are commonly used in biopharmaceutical production for the expression of therapeutic proteins. Here is some information about CHO cell culture media:

For Download Sample Report Click Here: https://www.marketinforeports.com/Market-Reports/Request-Sample/520660

Basal Media: Basal media form the foundation of CHO cell culture media and provide essential nutrients and growth factors necessary for cell growth. They typically contain a balanced mixture of amino acids, vitamins, inorganic salts, glucose or other energy sources, and buffering agents to maintain pH stability. Basal media are usually supplemented with serum or serum substitutes, such as fetal bovine serum (FBS) or chemically defined serum-free supplements, to provide additional nutrients and growth-promoting factors.

Serum and Serum-Free Media: Traditionally, CHO cell culture media have utilized serum, such as FBS, to enhance cell growth and productivity. However, serum can introduce batch-to-batch variability and potential contamination risks. To overcome these challenges, serum-free media formulations have been developed. These media contain defined components that can support CHO cell growth and protein production without the use of animal-derived serum. Serum-free media often incorporate recombinant growth factors, hormones, and specific nutrients to mimic the growth-promoting properties of serum.

Feed Media: CHO cell cultures often require supplementation with feed media during the production phase to enhance cell viability, productivity, and protein quality. Feed media provide additional nutrients, such as amino acids, vitamins, and energy sources, to sustain the cells during the production of recombinant proteins. Feed media are typically added periodically or continuously to the culture to maintain optimal conditions for protein synthesis and prevent nutrient depletion.

Specialized Media: Depending on the specific requirements of CHO cell lines or the desired outcomes of the production process, specialized media formulations may be used. These specialized media can include chemically defined media, animal-component-free media, or media optimized for specific CHO cell lines or expression systems. These formulations are designed to provide precise control over the culture conditions and maximize protein yield and quality.

Buffer Systems: CHO cell culture media often incorporate buffering systems to maintain a stable pH within the optimal range for cell growth. Common buffer systems used include bicarbonate, phosphate, or HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid). The choice of buffer system depends on the specific experimental setup and requirements.

It’s important to note that the composition and formulations of CHO cell culture media can vary among different manufacturers and laboratories. Optimization of media components and culture conditions is critical for achieving high cell viability, productivity, and protein quality in CHO cell cultures. Specific media formulations are typically tailored to the specific needs of the cell line and the intended application, and they are often developed through a combination of empirical optimization and scientific expertise.

[shital1998]

Biopharmaceutical Processing Equipment and Consumables Market - Global Opportunity Analysis and Industry Forecast (2022-2029)

Meticulous Research®– leading global market research company published a research report titled “Biopharmaceutical Processing Equipment and Consumables Market by Product Type {Filtration, Chromatography [Columns, Equipment], Disposable Bioreactors, Cell Culture Media, Shakers, Services), Application (Vaccine, mAb, R&D), and End User- Forecast to 2029.”

According to this latest publication from Meticulous Research, the global biopharmaceutical processing equipment and consumables market is expected to grow at a CAGR of 10.3% to reach $70.84 billion by 2029. Initiatives supporting the adoption of biopharmaceuticals, capacity expansions of biopharmaceutical manufacturing plants, and growing use of single-use technologies in commercial bioproduction are the factors driving the market growth.

Biopharmaceutical Processing Equipment and Consumables Market: Future Outlook

The global biopharmaceutical processing equipment and consumables market study presents, historical market data in terms of values (2020 and 2021), estimated current data (2022), and forecasts it for 2029 –by Product Type (Filtration Systems, Chromatography Systems {Resins, Columns, & Equipment}, Bioreactors {Reusable Bioreactors, Disposable/Single-use Bioreactors}, Cell Culture Products {Cell Culture Media [Cell Culture Media, by Physical Form–Dry Powder Media, Liquid Media], [Cell Culture Media, by Type–Off-the-Shelf Media, Custom Media], [Cell Culture Media Market, by Source-Chemically Defined Media, Natural Media], Reagents and Supplements, Cell and Cell Lines, Serum}, Mixing Systems, Bioprocessing Containers, Sterilizers, Centrifuges, Incubators, Shakers, Biosafety Cabinets, Other Consumables and Accessories, Services), Application (Commercial Bioproduction {Vaccine Manufacturing, mAb Production, Recombinant Protein Production, Cell and Gene Therapy Production}, Research and Development), End User (Biopharmaceutical/ Biotechnology Companies, Contract Development and Manufacturing Organizations and Contract Research Organizations (CDMOs/CROs), & Academics and Research Institutes), and Geography. The study also evaluates industry competitors and analyzes their market share at global and regional levels.

Download Free Sample PDF Copy: https://www.meticulousresearch.com/download-sample-report/cp_id=4200

Scope of the Report:

Global Biopharmaceutical Processing Equipment and Consumables Market, by Product Type

 Resins

 Columns

 Equipment

 Reusable      Bioreactors

 Disposable/Single-use      Bioreactors

   Dry Powder Media

   Liquid Media

     Off-the-Shelf Media

   Custom Media

     Chemically Defined Media

   Natural Media

  (Note: Other equipment and consumables include membrane adsorbers, cell disruption reagents, pipettes, syringes, vials, closures, tubing, connectors, and sensors)

Global Biopharmaceutical Processing Equipment and Consumables Market, by Application

 Vaccine      Manufacturing

 mAb      Production

 Recombinant      Protein Production

 Cell      and Gene Therapy Production

Global Biopharmaceutical Processing Equipment and Consumables Market, by End User

Biopharmaceutical/     Biotechnology Companies

Contract     Development and Manufacturing Organizations and Contract Research     Organizations (CDMOs/CROs)

Academics     and Research Institutes

 Biopharmaceutical Processing Equipment and Consumables Market, by Geography

 U.S.

 Canada

 Germany

 U.K.

 France

 Italy

 Spain

 Switzerland

 Rest      of Europe (RoE)

 China

 Japan

 India

 Rest      of APAC (RoAPAC)

Speak to Our Analyst: https://www.meticulousresearch.com/speak-to-analyst/cp_id=4200 Based on product type, the filtration systems segment is estimated to account for the largest share of the market in 2022. The technological developments in filtration technologies and accelerated developments of single-use filtration systems to meet the growing need for single-use bioprocessing systems are contributing to the largest market share.

Based on application, the market is segmented into commercial bioproduction and R&D. The commercial bioproduction segment is estimated to account for the largest share of the market in 2022, owing to the growing number of biopharmaceuticals in the clinical development and nearing patent expiry of biologics.

Based on end user, the biopharmaceutical/biotechnology companies segment is estimated to account for the largest share of the market in 2022. The largest revenue share is attributed to the growing demand for biopharmaceutical equipment for commercial bioproduction in biopharmaceutical/biotechnology companies.

Geographic Review:

This research report analyzes major geographies and provides comprehensive analysis for North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, Switzerland, and Rest of Europe), Asia-Pacific (China, Japan, India, and RoAPAC), Latin America, and Middle East & Africa.

North America is estimated to command the largest share of the biopharmaceutical processing equipment and consumables market in 2022, followed by Europe and Asia-Pacific. The U.S. is estimated to be the largest shareholding market in North America in 2022. An increase in the biotechnology R&D expenditure, the emergence of infectious diseases, supportive initiatives for increasing adoption of biosimilars, and large number of biopharmaceutical companies are some of the major factors driving the demand for biopharmaceutical processing equipment and consumables in the country.

BUY NOW: https://www.meticulousresearch.com/Checkout/94239620 Key Players

The key players operating in the global biopharmaceutical processing equipment and consumables market are 3M Company (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), Agilent Technologies, Inc (U.S.), Repligen Corporation (U.S.), Sartorius AG (Germany), Merck KGaA (Germany), Eppendorf AG (Germany), and Solaris Biotechnology Srl (Italy).

Key questions answered in the report-

Which are the high-growth market     segments in terms of product type, application, end user, and     regions/countries?

What was the historical market for     biopharmaceutical processing equipment and consumables across the globe?

What are the market forecasts and     estimates for the period 2022–2029?

What are the major drivers,     restraints, challenges, opportunities, and trends in the global market of     biopharmaceutical processing equipment and consumables?

Who are the major players in the     global biopharmaceutical processing equipment and consumables market?

How is the competitive landscape,     and who are the market leaders in the global biopharmaceutical processing     equipment and consumables market?

What are the recent developments in     the biopharmaceutical processing equipment and consumables market?

What are the different strategies     adopted by the major players in the biopharmaceutical processing equipment     and consumables market?

What are the geographical trends     and high growth regions/countries?

top 10 companies operating in Biopharmaceutical Processing Equipment And Consumables Market- https://meticulousblog.org/top-10-companies-in-biopharmaceutical-processing-equipment-and-consumables-market/

Contact Us: Meticulous Research® Email- sales@meticulousresearch.com Contact Sales- +1-646-781-8004 Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research Connect with us on Twitter- https://twitter.com/MeticulousR123

[mitalipingale]

https://webyourself.eu/blogs/426204/Cell-Culture-Media-Market-Size-Analysis-and-Forecast-2031

The Cell Culture Media Market in 2023 is US$ 4.58 billion, and is expected to reach US$ 11.7 billion by 2031 at a CAGR of 12.50%.

[healthcaremarketanalysis]

Cell Culture Media Market worth $13.0 billion by 2028

The global cell culture media market in terms of revenue was estimated to be worth $6.2 billion in 2023 and is poised to reach $13.0 billion by 2028, growing at a CAGR of 16.0% from 2023 to 2028. 

Download an Illustrative overview:

Browse in-depth TOC on "Cell Culture Media Market"

359 - Tables

42 - Figures

315 – Pages

In 2022, the serum-free media segment accounted for the largest share of the type segment in the cell culture media market.

On the basis of type, the cell culture media market is divided into serum-free media, classical media & salts, stem cell culture media, specialty media, chemically defined media, and other cell culture media. In 2022, the serum-free media segment holds for the bigest share of the market. Factors responsible for the growth of this segment includes various advantages or benefits of serum-free media over other types of cell culture media.

In 2022, the biopharmaceutical production segment accounted for the largest share of the application segment in the cell culture media market.

On the basis of application, the cell culture media market is categorized into biopharmaceutical production, diagnostics, drug discovery & development, tissue engineering & regenerative medicine, and other applications. The biopharmaceutical production segment is estimated to grow at the highest growth rate during the forecast period. Factors responsible for the growth include, the growing production of cell culture-based vaccines, and expansion of pharmaceutical industry. The biopharmaceutical production applications of cell culture media include the manufacturing of biologic-based products such as vaccines, monoclonal antibodies, and other therapeutic proteins (such as anticoagulants, enzymes, blood factors, hormones, interferons, growth factors, interleukins, engineered proteins, and thrombolytics, among others).

In 2022, the Asia Pacific region is the fastest-growing region of the cell culture media market.

On the basis of the region, the global cell culture media market has been segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. During the forecast period, the Asia Pacific market is estimated to register the highest CAGR during the forecast period. Increased focus of key market players on geographical expansion in emerging markets, favorable government policies and support for cell-based vaccines in the region and less manufacturing cost are some of the major factors anticipated to have positive impact on the market growth of Asia Pacific region.

Request Sample Pages:

Key Market Players:

Key players in the cell culture media market include Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Sartorius AG (Germany), Corning Incorporated (US), FUJIFILM Irvine Scientific, Inc. (Japan), Lonza Group AG (Switzerland), Becton, Dickinson and Company (US), Miltenyi Biotec (Germany), and among others.

Recent Developments:

In June 2023, Thermo fisher launched Tumoroid Culture Medium to accelerate development of novel cancer therapies.

In April 2023, FUJIFILM Irvine Scientific launched BalanCD CHO Media Platform Portfolio for Bioprocessing.

In March 2022, FUJIFILM Irvine Scientific acquired Shenandoah Biotechnology. The deal would help the company to provide customers with a single point of access for their life science research, discovery, and cell and gene therapy needs.

In January 2022, Cytiva and Nucleus Biologics LLC collaborated to enhance custom cell media development for cell and gene therapies.

Cell Culture Media Market Advantages:

Versatility: Cell culture media provide a versatile platform for the growth and maintenance of various types of cells, including primary cells, stem cells, and cell lines derived from different tissues and species. This versatility allows researchers to study and manipulate diverse cell populations, facilitating a wide range of applications in basic research, drug discovery, and regenerative medicine.

Reproducibility: High-quality cell culture media formulations are standardized and extensively tested, ensuring consistent and reproducible results across different experiments and laboratories. This reliability is essential for generating meaningful and reliable data, which is critical for the advancement of scientific knowledge.

Customizability: The cell culture media market offers customizable formulations to cater to specific cell types and experimental requirements. Researchers can optimize media components to suit the unique needs of their cells, enhancing cell growth, proliferation, and differentiation, ultimately leading to more accurate and reliable experimental outcomes.

Scalability: Cell culture media have been developed to support large-scale production of cells, making them integral to biopharmaceutical manufacturing. With the increasing demand for cell-based therapies and biologics, scalable media solutions play a vital role in ensuring the efficient and cost-effective production of therapeutic cells and products.

Safety and Purity: High-quality cell culture media are manufactured under stringent quality control standards to ensure the absence of contaminants that may compromise cell viability or introduce experimental artifacts. These safety measures are essential to maintain the integrity of research findings and the safety of biopharmaceutical products.

Reduced Dependency on Animal Models: Advanced cell culture media formulations have contributed to reducing reliance on animal models in research, as they allow scientists to conduct more relevant experiments using human or cell-based models. This ethical advantage aligns with the growing focus on reducing animal testing while still advancing scientific progress.

Technological Advancements: The cell culture media market continually evolves, incorporating technological advancements, such as serum-free or xeno-free formulations, to improve cell culture systems' efficiency and reproducibility. These innovations empower researchers to work with more physiologically relevant and defined conditions, yielding results that better translate to clinical applications.

Accelerated Drug Discovery: Robust cell culture media accelerate drug discovery processes by enabling high-throughput screening of potential drug candidates on various cell models. This expedites the identification of promising compounds, shortens development timelines, and reduces drug development costs.

Overall, the cell culture media market's advantages have revolutionized modern biomedical research, playing a pivotal role in advancing scientific knowledge, drug development, and regenerative medicine, while contributing to the growth of the biotechnology and pharmaceutical industries.

[market-insider]

Cell Culture Media Market 2022 | Serum-Free Media Segment Held The Largest Revenue Share

The global cell culture media market size is expected to reach USD 10.2 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 12.1% from 2022 to 2030. Expansion of biosimilars and biologics, growth in stem cell research, and emerging bio manufacturing technologies for cell-based vaccines are the major factors which are likely to drive the market. For instance, in October 2021, the Australian Government funded the Australian-led stem cell research through USD 25 million in grants.

The expansion of clear, regulatory approval paths for biosimilars in emerging markets is generating great opportunities for biosimilar monoclonal antibodies.  The availability of an approval pathway in the U.S., has led to new opportunities for bio manufacturers to enter major markets around the globe. Biosimilar versions of monoclonal antibodies have the probability to offer cost reductions of 25-30%, and many emerging market countries are vigorously developing pathways for approvals and are swiftly catching up. As this industry is expanding the key biopharmaceutical players are adopting robust culturing technologies to meet the increasing demand; thereby driving the growth of the market.

Gain deeper insights on the market and receive your free copy with TOC now @: Cell Culture Media Market Report

Moreover, there is growing interest in improving the stem cell culture, because this technology is being used extensively in research for studying the stem cell biology, as well as for therapeutic applications. Furthermore, funding related to this research field has augmented in recent years which has accelerated the growth of the market. In addition to this, key media manufacturers launched new products for stem cell research. For instance, in September 2021, Bio-Techne Corporation launched a novel medium for the maintenance and expansion of induced pluripotent stem cells having applications in both translational and research workflows.

The outbreak of COVID-19 pandemic has improved the demand for well-established cell-based vaccine production technologies. Moreover, it has given rise to a few scientific innovations, particularly in the production and testing of vaccine technology. For instance, the Vero line originated from the African green monkey kidney and has been extensively used for viral vaccine manufacturing. It has also been used for the development of various SARS-CoV variants. ProVeroTM1 Serum-free Medium is one such medium manufactured by Lonza Bioscience which is protein-free, and of non-animal origin designed to support the growth of Vero cells and MDCK.

Moreover, in many European countries, cell-based flu vaccines have been approved. A probable advantage of cell culture technology is that it authorizes faster start-up of the manufacturing of vaccines during the pandemic. Today, the development of superior biological models, the optimization of culture growth medium, and the reduced dependence on animal-derived components endure to drive the rapidly developing vaccine development.

On the other hand, ethical issues concerning the use of animal-derived products hinders the industry growth. For instance, FBS is collected from the blood of fetal calves is one of the major ethical issues of serum containing media. It is projected that 600,000 liters of FBS is achieved from up to 1.8 million bovine fetuses are produced globally every year, presenting momentous scientific and ethical challenges. To overcome this issue, numerous workshops were held in the past on the replacement of fetal bovine serum and possible ways to reduce the use of FBS in media.

[desaletushki]

Cell Culture Media Market Growth Factors

Cell Culture Media Market Growth & Trends

The global cell culture media market size is expected to reach USD 10.2 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 12.1% from 2022 to 2030. Expansion of biosimilars and biologics, growth in stem cell research, and emerging bio manufacturing technologies for cell-based vaccines are the major factors which are likely to drive the market. For instance, in October 2021, the Australian Government funded the Australian-led stem cell research through USD 25 million in grants.

The expansion of clear, regulatory approval paths for biosimilars in emerging markets is generating great opportunities for biosimilar monoclonal antibodies.  The availability of an approval pathway in the U.S., has led to new opportunities for bio manufacturers to enter major markets around the globe. Biosimilar versions of monoclonal antibodies have the probability to offer cost reductions of 25-30%, and many emerging market countries are vigorously developing pathways for approvals and are swiftly catching up. As this industry is expanding the key biopharmaceutical players are adopting robust culturing technologies to meet the increasing demand; thereby driving the growth of the market.

Moreover, there is growing interest in improving the stem cell culture, because this technology is being used extensively in research for studying the stem cell biology, as well as for therapeutic applications. Furthermore, funding related to this research field has augmented in recent years which has accelerated the growth of the market. In addition to this, key media manufacturers launched new products for stem cell research. For instance, in September 2021, Bio-Techne Corporation launched a novel medium for the maintenance and expansion of induced pluripotent stem cells having applications in both translational and research workflows.

The outbreak of COVID-19 pandemic has improved the demand for well-established cell-based vaccine production technologies. Moreover, it has given rise to a few scientific innovations, particularly in the production and testing of vaccine technology. For instance, the Vero line originated from the African green monkey kidney and has been extensively used for viral vaccine manufacturing. It has also been used for the development of various SARS-CoV variants. ProVeroTM1 Serum-free Medium is one such medium manufactured by Lonza Bioscience which is protein-free, and of non-animal origin designed to support the growth of Vero cells and MDCK.

Moreover, in many European countries, cell-based flu vaccines have been approved. A probable advantage of cell culture technology is that it authorizes faster start-up of the manufacturing of vaccines during the pandemic. Today, the development of superior biological models, the optimization of culture growth medium, and the reduced dependence on animal-derived components endure to drive the rapidly developing vaccine development.

On the other hand, ethical issues concerning the use of animal-derived products hinders the industry growth. For instance, FBS is collected from the blood of fetal calves is one of the major ethical issues of serum containing media. It is projected that 600,000 liters of FBS is achieved from up to 1.8 million bovine fetuses are produced globally every year, presenting momentous scientific and ethical challenges. To overcome this issue, numerous workshops were held in the past on the replacement of fetal bovine serum and possible ways to reduce the use of FBS in media.

For More Details: Cell Culture Media Market

[rootsanalysis-blog]

VIRAL VACCINE CELL CULTURE MEDIA: OVERALL MARKET LANDSCAPE

Innovation is considered to be one of the key drivers of the pharmaceutical industry. Over the past few decades, various technological advances and a few fortuitous discoveries have significantly changed the practice of medicine. One such advancement that came into light was the development of vaccines, which have demonstrated significant therapeutic potential.

  Over time, vaccine research has evolved significantly, which is now being driven by several innovative technologies, including those involving the use of recombinant deoxyribonucleic acid (DNA) and nucleic acids. Further, with the discovery of more disease targets, players engaged in vaccine development have shifted their focus towards the development of vaccines that target a myriad of disease indications other than infectious diseases. In order to mitigate the aforementioned challenges, pharma and biotech companies are gradually adopting viral vaccine cell culture media for vaccines manufacturing. 

 A vaccine is a biological substance that is used to stimulate the host’s immune system against a specific disease. It is worth highlighting those vaccines are also referred to as immunizers, due to their ability to take advantage of the host’s natural immune system to prevent illnesses. Generally, the vaccines contain a weakened or an inactivated (killed) form of a virus / a small (in virulent) part of the virus, which is called the antigen. Vaccines help the immune system recognize the antigen as a foreign entity or invading germ, thereby, resulting in the production of antibodies. This process aids the immune system in generating a memory against the specific pathogen so that if the host is attacked by the same pathogen in the future, the body can generate an illicit response.

 To request a sample copy / brochure of this report, please visit link

https://www.rootsanalysis.com/reports/viral-vaccine-cell-culture-media-market/request-sample.html

 Viral vaccines were first produced in the early 1940s, using embryonated chicken eggs to replicate a broad variety of viruses. Over 30 human vaccines, manufactured using this technique, have been licensed; however, the production capacity associated with this method was limited due to the unavailability of fertilized eggs. Further, in 1950s, an alternative technology based on animal cell culture, which used primary cells as substrate, was developed. Then, in the late 1960s, continuous cell lines were recognized as suitable hosts for human vaccine production, however, the first production process using this technique was established in 1977. One of the key objectives of this report was to evaluate the current opportunity and the future potential associated with the viral vaccine cell culture media market, over the coming decade. We have developed an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. 

  Cell cultures can be broadly classified into two categories, namely adherent and suspension cell cultures.

§  Adherent Cell Culture: As the name suggests, these cells must be attached to a surface to grow. These cells can be cultured in flasks, roller bottles and other cell culture vessels capable of handling anchorage-dependent cell types. As most of the tissue-derived cells in the body require an extracellular matrix for growth and proliferation, this method provides scalable options, such as mimicking a microenvironment. In addition, some adherent platforms provide the benefit of visualization through a microscope.

§  Suspension Cell Culture: In this process, cells or cluster of cells are allowed to function and multiply in an agitated growth medium. Suspension cells can be cultured in small-scale vessels, such as spinner flasks or large-scale vessels (single-use bioreactors). These cells offer a vast range of scalability, thereby, making it a preferred option for manufacturers in order to increase their operational efficacy. In fact, the nutrients can be continually adjusted in these cell cultures, depending on their usage and need of the cells. However, suspension cell culture lacks the benefit of direct visualization. In addition, the shear force and stress exerted due to the continuous agitation of the media in suspension culture are detrimental to many cell types, especially anchorage-dependent primary and stem cells.

 For additional details, please visit link https://www.rootsanalysis.com/reports/viral-vaccine-cell-culture-media-market.html or email sales@rootsanalysis.com

 You may also be interested in the following titles:

1.       Targeted protein degradation market, 2022-2035

2.       Cell Therapy Manufacturing Market, 2021-2030

3.       Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 Contact:

Ben Johnson

+1 (415) 800 3415

+44 (122) 391 1091

Ben.johnson@rootsanalysis.com